(HealthDay News) – For patients with heart failure, Coenzyme Q10 (CoQ10) supplementation is associated with a significantly lower occurrence of hospitalizations for heart failure and with reduced cardiovascular and all-cause mortality, according to a study presented at the European Society of Cardiology’s annual Heart Failure Congress, held from May 25–28 in Lisbon, Portugal.
Svend Aage Mortensen, MD, ScD, from the Copenhagen University Hospital in Denmark, and colleagues randomized patients with New York Heart Association (NYHA) Class III or IV heart failure who were receiving current pharmacologic therapy to 100mg CoQ10 three times daily (202 patients) or placebo (218 patients).
The researchers observed a trend toward reduced N-terminal pro-brain natriuretic peptide in the CoQ10 group after three months. After two years of follow-up, significant improvement in the NYHA class was seen in the CoQ10 group (P=0.047). The primary end point of time to first major cardiovascular event was reached by significantly fewer patients in the CoQ10 group vs. the placebo group (14% vs. 25%; hazard ratio, 2). Cardiovascular mortality, all-cause mortality, and the occurrence of heart failure hospitalizations were also significantly lower in the CoQ10 group. Fewer adverse events were experienced by patients in the CoQ10 group vs. the placebo group.
“CoQ10 is the first medication to improve survival in chronic heart failure since angiotensin converting enzyme inhibitors and beta blockers more than a decade ago and should be added to standard heart failure therapy,” Mortensen said in a statement.
The study was funded in part by Pharma Nord and the Kaneka Corporation of Osaka, both manufacturers of dietary supplements, and the International Coenzyme Q10 Association.